RA PROGRESSION
INTERRUPTED¹

No structural damage progression was observed at week 52 in 55.6% and in 47.8% of patients receiving KEVZARA 200 mg + MTX or 150 mg + MTX, compared with 38.7% of patients receiving placebo + MTX (defined by change in Total Sharp Score ≤0).¹

LEARN MORE >> KEVZARA is indicated for treatment of adult patients with moderately to severely
active rheumatoid arthritis (RA) who have had an inadequate response or
intolerance to one or more disease-modifying antirheumatic drugs (DMARDs).